| 10.45 0.24 (2.35%) | 10-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.33 | 1-year : | 15.57 |
| Resists | First : | 11.42 | Second : | 13.33 |
| Pivot price | 10.41 |
|||
| Supports | First : | 9.59 | Second : | 8.46 |
| MAs | MA(5) : | 10.5 |
MA(20) : | 10.21 |
| MA(100) : | 8.54 |
MA(250) : | 7.46 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 39.3 |
D(3) : | 51.8 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 11.42 | Low : | 5.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ XERS ] has closed below upper band by 47.4%. Bollinger Bands are 8.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.5 - 10.54 | 10.54 - 10.58 |
| Low: | 10 - 10.04 | 10.04 - 10.09 |
| Close: | 10.37 - 10.45 | 10.45 - 10.52 |
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
Sun, 25 Oct 2026
Why Xeris Biopharma Holdings (XERS) Is Down 6.1% And What's Next - Simply Wall Street
Fri, 23 Oct 2026
Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Ov - GuruFocus
Fri, 23 Oct 2026
Xeris Biopharma Holdings, Inc. Estimates – NASDAQ:XERS - TradingView
Thu, 22 Oct 2026
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Business Wire
Tue, 20 Oct 2026
Xeris Biopharma Holdings Inc (XERS) Shares Surge 6.2% -- What GF Score of 65 Tells Investors - GuruFocus
Tue, 06 Oct 2026
Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 182 (M) |
| Shares Float | 176 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 60.6 (%) |
| Shares Short | 7,200 (K) |
| Shares Short P.Month | 8,040 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | -5.2 % |
| Operating Margin | 5.6 % |
| Return on Assets (ttm) | 6.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 28.7 % |
| Gross Profit (p.s.) | 1.59 |
| Sales Per Share | 1.83 |
| EBITDA (p.s.) | 0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 57 (M) |
| Levered Free Cash Flow | 52 (M) |
| PE Ratio | -104.5 |
| PEG Ratio | 0 |
| Price to Book value | -174.17 |
| Price to Sales | 5.68 |
| Price to Cash Flow | 33.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|